Scale Your Vaccine Development With Path-To-PAD

The COVID-19 pandemic underscored the urgent need for a fast, efficient, and scalable vaccine production process. The Vaccine Path-To-PAD (Process and Analytical Development) program offers a straightforward approach to maximize yields early in development, leveraging deep expertise in vaccines, robust expression platforms, and high-quality Vero and Quail cell lines.

Our team of process development experts conducts comparability studies for live virus, viral vector, or oncolytic virus projects, enabling data-driven decisions on the best scale-up platform for future manufacturing. By evaluating your cell line productivity against Resilience's Vero and Quail cell line platforms, we help you select the optimal expression system to enhance yields.

The program also details the ideal combination of cell line, bioreactor, and expansion method tailored to your project, ensuring maximum yield from the outset. Our goal is to expand and accelerate your vaccine yields while ensuring product comparability, providing a solid manufacturing scale-up strategy for swift production.

Resilience's Path-To-PAD program delivers hands-on vaccine expertise to expedite the development of robust and scalable processes. Our potency assay expertise mitigates historical challenges of cell-based assays, such as high variability, to speed up sample processing times. With our program, you can scale your vaccine production efficiently, maximizing yields to combat the next life-threatening disease.